Metabolic regulation of osteoclast differentiation and function

The osteoclast is a giant cell that resorbs calcified matrix by secreting acids and collagenolytic enzymes. The molecular mechanisms underlying metabolic adaptation to the increased biomass and energetic demands of osteoclastic bone resorption remain elusive. Here we show that during osteoclastogenesis the expression of both glucose transporter 1 (Glut1) and glycolytic genes is increased, whereas the knockdown of hypoxia‐inducible factor 1‐alpha (Hif1α), as well as glucose deprivation, inhibits the bone‐resorbing function of osteoclasts, along with a suppression of Glut1 and glycolytic gene expression. Furthermore, the expression of the glutamine transporter solute carrier family 1 (neutral amino acid transporter), member 5 (Slc1a5) and glutaminase 1 was increased early in differentiation, and a depletion of L‐glutamine or pharmacological inhibition of the Slc1a5 transporter suppressed osteoclast differentiation and function. Inhibition of c‐Myc function abrogated osteoclast differentiation and function, along with a suppression of Slc1a5 and glutaminase 1 gene expression. Genetic and pharmacological inhibition of mammalian target of rapamycin (mTOR), as well as the activation of adenosine monophosphate (AMP)‐activated protein kinase (AMPK), inhibited osteoclastogenesis. Thus, the uptake of glucose and glutamine and utilization of the carbon sources derived from them, coordinated by HIF1α and c‐Myc, are essential for osteoclast development and bone‐resorbing activity through a balanced regulation of the nutrient and energy sensors, mTOR and AMPK. © 2013 American Society for Bone and Mineral Research

[1]  Claire Redin,et al.  A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans , 2012, Science.

[2]  J. Veuthey,et al.  Identification and Functional Expression of the Mitochondrial Pyruvate Carrier , 2012, Science.

[3]  T. Soga,et al.  mTORC1 is essential for leukemia propagation but not stem cell self-renewal. , 2012, The Journal of clinical investigation.

[4]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[5]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[6]  M. Birnbaum,et al.  ADaPting to Energetic Stress , 2011, Science.

[7]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[8]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[9]  Georg Schett,et al.  Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[10]  D. Sabatini,et al.  Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids , 2010, Cell.

[11]  A. Leutz,et al.  Rapamycin and the transcription factor C/EBPβ as a switch in osteoclast differentiation: implications for lytic bone diseases , 2009, Journal of Molecular Medicine.

[12]  H. Knowles,et al.  Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis , 2009, The Journal of pathology.

[13]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[14]  H. Aburatani,et al.  Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation , 2009, Nature Medicine.

[15]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[16]  E. Wagner,et al.  Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia , 2008, Nature.

[17]  T. P. Neufeld,et al.  Regulation of TORC1 by Rag GTPases in nutrient response , 2008, Nature Cell Biology.

[18]  David M. Sabatini,et al.  The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1 , 2008, Science.

[19]  S. Kang,et al.  Osteoclast Precursors Display Dynamic Metabolic Shifts toward Accelerated Glucose Metabolism at an Early Stage of RANKL-Stimulated Osteoclast Differentiation , 2007, Cellular Physiology and Biochemistry.

[20]  Russell G. Jones,et al.  Revving the engine: signal transduction fuels T cell activation. , 2007, Immunity.

[21]  Mone Zaidi,et al.  Skeletal remodeling in health and disease , 2007, Nature Medicine.

[22]  Chao Wan,et al.  The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. , 2007, The Journal of clinical investigation.

[23]  H. Takayanagi.  Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems , 2007, Nature Reviews Immunology.

[24]  K. Hruska,et al.  Akt1/Akt2 and Mammalian Target of Rapamycin/Bim Play Critical Roles in Osteoclast Differentiation and Survival, Respectively, Whereas Akt Is Dispensable for Cell Survival in Isolated Osteoclast Precursors* , 2005, Journal of Biological Chemistry.

[25]  H. Lane,et al.  Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. , 2004, Bone.

[26]  G. Wesolowski,et al.  M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase , 2003, Cell Death and Differentiation.

[27]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[28]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[29]  T. Arnett,et al.  Hypoxia is a major stimulator of osteoclast formation and bone resorption , 2003, Journal of cellular physiology.

[30]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[31]  D. Hall,et al.  Transcription From the Tartrate‐resistant Acid Phosphatase Promoter Is Negatively Regulated by the Myc Oncoprotein , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  P. Stashenko,et al.  c‐myc Is Required for Osteoclast Differentiation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  E. Wagner,et al.  Reaching a genetic and molecular understanding of skeletal development. , 2002, Developmental cell.

[34]  T Kobayashi,et al.  Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. , 2001, Genes & development.

[35]  W M Miller,et al.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. , 2001, Biophysical journal.

[36]  M. V. Vander Heiden,et al.  In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. , 2000, Molecular cell.

[37]  J. Williams,et al.  Regulation of osteoclastic bone resorption by glucose. , 1997, Biochemical and biophysical research communications.

[38]  Y. Kanai,et al.  Cloning and Functional Characterization of a System ASC-like Na+-dependent Neutral Amino Acid Transporter* , 1996, The Journal of Biological Chemistry.

[39]  Tsung-Cheng Chang,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[40]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[41]  Matthew J. Silva,et al.  SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Medicine.

[42]  S. Weinhouse.  On respiratory impairment in cancer cells. , 1956, Science.